Form 4: OnKure Therapeutics CEO Sells Shares to Cover Tax Obligations

Nicholas A. Saccomano, CEO of OnKure Therapeutics, sold shares of Class A Common Stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On April 4, 2025, Nicholas A. Saccomano, the President and CEO of OnKure Therapeutics, sold 358 shares of Class A Common Stock at a weighted average price of $3.3276.
• On April 7, 2025, Saccomano sold an additional 516 shares of Class A Common Stock at a weighted average price of $2.671.
• These sales were executed to cover tax withholding obligations related to the vesting of restricted stock units (RSUs) under the company's 2023 RSU Equity Incentive Plan.
• Following these transactions, Saccomano directly owns 3,682 shares of Class A Common Stock, some of which are RSUs representing a contingent right to receive one share of Class A Common Stock, subject to vesting schedules and conditions.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (selling shares to cover taxes on vested RSUs) and doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The sale of shares by the CEO could have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect on shareholders.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, OnKure Therapeutics, Saccomano, Insider Trading, Share Sale, Equity Incentive Plan, Restricted Stock Units, Tax Withholding